MF3d
- Olema Pharmaceuticals (OLMA), which is developing the estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) palazestrant, is down ~15% in after-hours trading Friday after AstraZeneca (AZN) disclosed the failure of its own SERD and
